Products & Services
CMC Development
Peptide NCES
Oligonucleotide NCEs
Commercial APIs
Commercial NCEs
Commercial Generics
Research & Specialties
Catalog Peptides
Custom Peptide Synthesis
Amino Acid Derivatives
Diagnostics
Cosmetic Peptides
Services & Capabilities
Project Management
Quality & Regulatory
Analytical capabilities
GMP Production
Research Grade Production
Supply & vertical integration
About Bachem
Company overview
Our Purpose
Our vision & strategy
Our Leadership
Our History
Our Locations
Innovation
Innovation matters
Innovation collaborations
Sustainability
People & culture
Safeguarding the environment
Acting ethically
Investors & Media
Reports & Presentations
Financial events
Media Library
Press archive
News & Events
News
Events
Careers
Contact
Select Page
Results of the capital increase
May 08, 2019
Only available in the German version.
Download
←
Peptide Trends April 2019
Peptide Trends May 2019
→
Search for:
GalNAc conjugates: Delivery service to the liver!
Bachem announces the launch of their new website
Change in the Board of Directors of Bachem Holding AG
Bachem reports excellent results in 2020 – Sales exceed 400 million CHF for the first time
Peptide Trends February 2021
A New Turn in Peptide Purification
Innovation management
Peptide Trends January 2021
Bachem receives the Top Innovator Award from Alpora
Bachem Expanding into Oligonucleotides
Peptide Trends November 2020
Microspheres and Nanoparticles for Peptide Delivery
Changes to the Bachem Corporate Executive Committee
Peptide Trends October 2020
Peptide Trends September 2020
Oligonucleotide Trends September 2020
First half of 2020: Record sales and faster growth
Peptide Trends July 2020
Peptide Trends June 2020
Peptide Trends May 2020
